MedTech Innovator, in collaboration with Asia Pacific Medical Technology Association, recently unveiled a list of the 20 companies it has chosen to participate in its third annual Asia Pacific Accelerator program, according to a press release.
“MedTech Innovator Asia Pacific offers best-in-class start-ups with opportunities to work with investors, business leaders and allied service professionals in the medtech industry to help drive commercialization of life-changing technologies throughout the region,” a recent press release states.
This year’s cohort companies will also compete for up to $300,000 in cash prizes.
“This year’s selected cohorts for our Asia Pacific Accelerator program represent some of the region’s most promising entrepreneurs looking to solve significant real-world problems in health care,” CEO of MedTech Innovator, Paul Grand, said. “Together with our sponsors, we look forward to helping them bring their innovations to patients in need.”
More than 250 businesses applied for the program, but only four startups belonging to this year’s Asia Pacific Cohort were selected to compete in the final event of APACMed’s Medtech Forum 2022, scheduled to take place on Sept. 26-27 in Singapore. The forum will showcase the solutions suggested by the 20 accelerator companies.
The winning company will be chosen based on votes submitted by the audience, collect prizes and will be crowned 2022 MedTech Innovator Asia Pacific Winner and be eligible to win a non-dilutive cash prize. Various local health care industry leaders, providers and investors will attend the meeting.
The sponsors supporting the program include Johnson & Johnson Medical Devices Companies, Align Technology, Nipro Medical Corporation, Oliver Healthcare Packaging, Jabil, Siemens Healthineers, Cambridge Consultants and Enterprise Singapore. The MedTech Innovator Asia Pacific Program is held in partnership with APACMed.
“Our continued partnership with MedTech Innovator on its Asia Pacific Accelerator aligns with our mission to help shape the future of health care across our region,” said Harjit Gill, CEO of APACMed. “The 2022 cohorts stand to make a significant difference in how patients are cared for across multiple disease states and conditions.”